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Background and aims: Mutations in RYR1 lead to various neuromuscular phenotypes including 
malignant hyperthermia susceptibility and Rhabdomyolysis (RM). We report the use of oral 
dantrolene as a prophylactic treatment for RYR1-related RM. 
Methods: Case report. 
Results: Three patients were prescribed 25mg of dantrolene to take orally up to a 
maximum of four times a day at the onset of symptoms in an attempt to stop 
progression of the RM episodes. All patients reported benefits with no drug-related side 
effect. 
Conclusion: In the short term use of low dose dantrolene-associated benefits appear to 
outweigh risks in the management of patients with recurrent rhabdomyolysis due to 
mutations in RYR1, in particular ad hoc use during symptoms might possibly prevent or 
abort an attack of RM. Undertaking a randomised, double-blinded, placebo controlled 
clinical trial to assess risks and benefits of dantrolene in this group of patients could help 
to evaluate the role this drug in preventing RM due to RYR1 mutations in the future. 
 
